Molecular Biology Reports

, Volume 36, Issue 6, pp 1323–1329

Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease

  • Zhi-Jian Yang
  • You-Rong Zhang
  • Bo Chen
  • Shu-Lan Zhang
  • En-Zhi Jia
  • Lian-Sheng Wang
  • Tie-Bing Zhu
  • Chun-Jian Li
  • Hui Wang
  • Jun Huang
  • Ke-Jiang Cao
  • Wen-Zhu Ma
  • Bin Wu
  • Li-Sheng Wang
  • Chu-Tse Wu
Article

DOI: 10.1007/s11033-008-9315-3

Cite this article as:
Yang, ZJ., Zhang, YR., Chen, B. et al. Mol Biol Rep (2009) 36: 1323. doi:10.1007/s11033-008-9315-3

Abstract

Objective Therapeutic angiogenesis is a new strategy for treatment of vascular insufficiency. Hepatocyte growth factor (HGF)-induced angiogenesis has been applied to induce the neovascularization of ischemic adult tissues in preclinical studies. This report summarizes a phase I clinical trial on the safety of adenovirus-mediated human HGF (Ad-HGF) gene transfer to treat clinically significant coronary artery disease. Methods The 18 patients with severe and diffused triple vessel disease determined by coronary angiography, 1–3 of the main coronary arteries not amenable to bypassing grafting and to catheter-based revascularization were assigned to 3 study groups according to the dose of Ad-HGF (from low to high), and the total dose as follows: 5 × 109 pfu (group A, n = 6); 1 × 1010 pfu (group B, n = 6); 2 × 1010 pfu (group C, n = 6). Arterial gene transfer was performed by over-the wire balloon to the distal of the accessible artery or otherwise the ostium of the target vessels by diagnostic coronary catheter. General safety parameters and cardiac-specific parameters were measured through the preoperative period and on day 7, 21, and 35 postoperatively. The safety and tolerance of Ad-HGF for patients were evaluated according to functional and cytological assessments. Results During the acute phase up to day 35 and at 11–14 months of follow-up there were no serious adverse events. A mild fever during the first 3 days was not present at day 4, and no long term or paroxysmal fever was found. There were no acute alterations in hemodynamic parameters and the electrocardiogram remained normal. No serious pericardial effusion was reported and there were no arrhythmia on Holter registrations. Moreover, the serum levels of HGF were not changed and the serum anti-adenovirus in the patients was not detected up to day 35. Conclusions The present study demonstrates that it is feasible to safely use an adenovirus gene-transfer vector to deliver the human hepatocyte growth factor gene to individuals with clinically significant coronary artery disease by direct intracoronary injection. However, a great deal of additional work must be done before administration of Ad-HGF can be recommended for clinical practice.

Keywords

Angiogenesis Gene therapy Genetics Coronary disease 

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Zhi-Jian Yang
    • 1
  • You-Rong Zhang
    • 2
  • Bo Chen
    • 1
  • Shu-Lan Zhang
    • 1
  • En-Zhi Jia
    • 1
  • Lian-Sheng Wang
    • 1
  • Tie-Bing Zhu
    • 1
  • Chun-Jian Li
    • 1
  • Hui Wang
    • 1
  • Jun Huang
    • 1
  • Ke-Jiang Cao
    • 1
  • Wen-Zhu Ma
    • 1
  • Bin Wu
    • 2
  • Li-Sheng Wang
    • 2
  • Chu-Tse Wu
    • 2
  1. 1.Department of Cardiovascular MedicineThe First Affiliated Hospital of Nanjing Medical UniversityNanjingPeople’s Republic of China
  2. 2.Department of Experimental HematologyBeijing Institute of Radiation MedicineBeijingPeople’s Republic of China

Personalised recommendations